scholarly journals Financial Impact of Intraviteal Ranibizumab or Aflibercepte for Neovascular Age-Related Macular Degeneration and for Macular Edema Secondary to Central Retinal Vein Occlusion Coverage for a Health Care System of Public Employees Located in Northeast Brazil Between July 2015 and December 2015

2016 ◽  
Vol 19 (7) ◽  
pp. A567-A568
Author(s):  
NN de Souza ◽  
Jd Silva ◽  
Sd Silva ◽  
CS Novis
Keyword(s):  
Health Care ◽  
Macular Edema ◽  
Central Retinal Vein Occlusion ◽  
Age Related Macular Degeneration ◽  
Financial Impact ◽  
Northeast Brazil ◽  
Public Employees ◽  
Vein Occlusion ◽  
Age Related ◽  
Central Retinal Vein

Evaluation of pain during intravitreal aflibercept injections

2017 ◽  
Vol 28 (1) ◽  
pp. 63-67 ◽  
Author(s):  
Sibel Doguizi ◽  
Mehmet A. Sekeroglu ◽  
Merve Inanc ◽  
Mustafa A. Anayol ◽  
Pelin Yilmazbas
Keyword(s):  
Diabetes Mellitus ◽  
Macular Edema ◽  
Age Related Macular Degeneration ◽  
Single Institution ◽  
Analog Scale ◽  
Vein Occlusion ◽  
Pain Scores ◽  
Age Related ◽  
Intravitreal Aflibercept ◽  
Central Retinal Vein

Purpose: To evaluate the pain associated with intravitreal aflibercept injections. Methods: The study included 119 patients who received intravitreal aflibercept injection at a single institution. Pain was evaluated by visual analog scale (VAS) immediately after the injection of 2 mg/0.05 mL aflibercept into the vitreous cavity using a 27-G needle. Additional variables including age, sex, indication for the injection, injection site by quadrant (superotemporal or inferotemporal), position during injection (sitting or supine), number of previous intravitreal injections in the study eye, presence of diabetes mellitus or hypertension, and lens status (phakic or pseudophakic) were recorded and assessed with self-reported pain scores. Results: Pain scores on the VAS ranged from 9 to 70, with a median of 18. Indications for injection included diabetic macular edema (21.0%), macular edema secondary to central retinal vein occlusion (12.6%), and neovascular age-related macular degeneration (66.38%). Pain did not significantly correlate with any of the recorded variables. Conclusions: This is the first series evaluating the pain associated with intravitreal aflibercept injections. We demonstrated that pain associated with intravitreal aflibercept injection is generally mild with low pain scores.

Eyes

2019 ◽  
pp. 239-260
Author(s):  
Tanya M. Monaghan ◽  
James D. Thomas
Keyword(s):  
Diabetic Retinopathy ◽  
Retinal Detachment ◽  
Optic Atrophy ◽  
Central Retinal Vein Occlusion ◽  
Age Related Macular Degeneration ◽  
Hypertensive Retinopathy ◽  
Vein Occlusion ◽  
Age Related ◽  
Optic Disc Swelling ◽  
Central Retinal Vein

This chapter concerns ophthalmology, and covers red eye, diabetic retinopathy, hypertensive retinopathy, optic disc swelling, glaucoma, optic atrophy, cataracts, central retinal vein occlusion, retinal detachment, age-related macular degeneration, and cytomegalovirus retinitis.

Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study

2014 ◽  
Vol 158 (5) ◽  
pp. 1032-1038.e2 ◽  
Author(s):  
Yuichiro Ogura ◽  
Johann Roider ◽  
Jean-François Korobelnik ◽  
Frank G. Holz ◽  
Christian Simader ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Phase 3 ◽  
Vein Occlusion ◽  
Intravitreal Aflibercept ◽  
Central Retinal Vein

scholarly journals Intraocular Injection of Stivant® (A Biosimilar to Bevacizumab): A Case Series

2021 ◽  
Author(s):  
Ahmad Mirshahi ◽  
Alireza Lashay ◽  
Hamid Riazi-Esfahani ◽  
Nazanin Ebrahimiadib ◽  
Hassan Khojasteh ◽  
...  
Keyword(s):  
Macular Edema ◽  
Intravitreal Injection ◽  
Case Series ◽  
Age Related Macular Degeneration ◽  
Intraocular Injection ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
Limited Experience ◽  
The Mean

Purpose: To report the results of intravitreal injection of a bevacizumab biosimilar called Stivant®. Methods: This prospective interventional case series was conducted on eyes with neovascular age-related macular degeneration (nAMD), retinal vein occlusion (RVO), and diabetic macular edema (DME). Stivant® was injected in three consecutive months and changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline and monthly up to one month after the third injection. Results: Three hundred and eighty-five eyes with DME (234 eyes, 61%), nAMD (87 eyes, 22%), and macular edema secondary to RVO (64 eyes, 17%) were enrolled. The mean ± standard deviation age of the patients was 61.7 ± 7.20 years. The mean BCVA and CMT changed from 0.63 ± 0.3 to 0.51 ± 0.3 LogMAR (P = 0.12 ) and from 420.4 ± 47.3μm at baseline to 316.7 ± 50.6 μm (P < 0.001) in the DME group; from 0.79 ± 0.3 to 0.68 ± 0.3 LogMAR (P = 0.19) and from 376.1 ± 31.7 μm to 303 ± 31.3 μm (P = 0.019) in the nAMD group; and from 0.81 ± 0.4 to 0.63 ± 0.4 LogMAR (P = 0.05) and from 424.21 ± 18 μm to 303.4 ± 18.8 μm (P < 0.001) in the RVO group, respectively. Conclusion: Our limited experience showed that the intravitreal injection of Stivant® was well tolerated. Although the results of this case series showed relative improvement in CMT one month after the last injection of Stivant®, BCVA improvement was statistically significant only in the RVO group. This would be essential to design a randomized clinical trial to evaluate the non-inferiority of Stivant® in comparison to bevacizumab.

Sign in / Sign up

Export Citation Format

Share Document